INTRODUCTION
thrombosis, Frailty
THROMBOSIS, EVENTS, SYNDROME
Frailty is a geriatric syndrome of vulnerability, common in older adults, that increases the risk of cardiovascular events, functional decline, morbidity, and mortality (Afilalo et al., Canakinumab is a therapeutic monoclonal antibody that targets IL‐1β blockade leading to reductions in both IL‐6 and the hepatic acute phase reactant C‐reactive protein (CRP). In the recent multinational randomized placebo controlled canakinumab anti‐inflammatory thrombosis outcome study (CANTOS), canakinumab was shown to significantly reduce rates of major adverse cardiovascular events (MACE) (Ridker et al., The geroscience hypothesis suggests that drugs impacting multiple aspects of aging biology, such as the hallmarks of aging (Lopez‐Otin et al., 